Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

PURPOSE Evaluation of the relationship between plasminogen activator inhibitor-1 (PAI-1) and the metastatic potential of primary breast cancer, and to compare the prognostic impact of PAI-1 in multivariate analysis with those of conventional prognostic factors, including steroid-hormone receptors, and those of urokinase plasminogen activator (uPA), pS2-protein (PS2), and cathepsin D. PATIENTS AND METHODS Cell biologic prognostic factors were analyzed in 657 cytosols routinely prepared from frozen-tissue biopsies that were submitted to our laboratory for the assessment of steroid-hormone receptor status. The median duration of follow-up in patients still alive at the time of analysis was 48 months. Estrogen receptor (ER) and progesterone receptor (PgR) status were assessed by radioligand binding assay, PS2, and cathepsin D by radiometric immunoassay, and uPA and PAI-1 by enzyme-linked immunosorbent assay (ELISA). RESULTS PAI-1 levels were found to be strongly positively correlated with the rates of relapse (P < .0001) and death (P < .001). Relating the levels of PAI-1 with those of other cytosolic prognostic factors, we found a positive association with the metastasis-related proteases uPA (P < .0001) and cathepsin D (P < .0001). On the other hand, PAI-1 levels were found to be negatively correlated with ER (P < .005) and PgR (P < .001), and the estrogen-regulated pS2-protein (P < .001), which are proteins associated with a favorable prognosis. In multivariate regression analysis for 5-year relapse-free survival, and using an optimized cutoff point for discrimination between PAI-1-positive and -negative, independent predictors of the rate of relapse were found to be PAI-1 (P < .0001) and uPA (P = .01) of the cytosolic parameters, and tumor size, lymph node status, and premenopausal age of the clinical parameters. In multivariate analysis in patients with node-negative disease, only PAI-1 (P < .001) and tumor size (P = .03) were positively and premenopausal age negatively (P < .001) associated with the rate of relapse. In patients with node-positive disease, PAI-1 (P < .001), uPA (P = .02), tumor size (P < .001), and the number of positive lymph nodes (P < .001) were all positively associated with the rate of relapse. CONCLUSION We conclude that the PAI-1 level measured in routinely prepared cytosols is an important parameter to predict the metastatic potential in both node-negative and node-positive human primary breast cancer.

[1]  Giampietro Gasparini,et al.  Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .

[2]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[3]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Jänicke,et al.  Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. , 1993, British Journal of Cancer.

[5]  R. Dickson,et al.  The role of cathepsin D in the invasiveness of human breast cancer cells. , 1993, Cancer research.

[6]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[7]  T. Visakorpi,et al.  Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Catherine,et al.  Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. , 1993, Cancer research.

[9]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[10]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[11]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[12]  W. McGuire,et al.  Prognosis and treatment decisions in patients with breast cancer without axillary node involvement , 1992, Cancer.

[13]  R Poulsom,et al.  Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. , 1992, The American journal of pathology.

[14]  E. Appella,et al.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. , 1992, The Journal of biological chemistry.

[15]  T. Hurskainen,et al.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. , 1992, Cancer research.

[16]  T. Urano,et al.  Plasminogen activator system in human breast cancer , 1992, International journal of cancer.

[17]  M. Duffy,et al.  Type‐1 plasminogen activator inhibitor in human breast carcinomas , 1992, International journal of cancer.

[18]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[19]  A. Desplaces,et al.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. , 1991, British Journal of Cancer.

[20]  C. Fellbaum,et al.  Immunolocalization of urokinase‐type plasminogen activator in adenomas and carcinomas of the colorectum , 1991, Histopathology.

[21]  K. Danø,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[22]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[23]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[24]  T. Urano,et al.  Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. , 1991, Thrombosis research.

[25]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[26]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[27]  B E Hillner,et al.  Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. , 1991, The New England journal of medicine.

[28]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[29]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.

[30]  L. Kirkeby,et al.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. , 1991, The American journal of pathology.

[31]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[32]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[33]  L. Orci,et al.  Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene , 1990, Cell.

[34]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[35]  K. Danø,et al.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. , 1990, The Journal of biological chemistry.

[36]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[37]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[38]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[39]  J. Foekens,et al.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.

[40]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[41]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[42]  V. Devita.  Breast Cancer Therapy: Exercising All Our Options , 1989 .

[43]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[44]  D. Loskutoff,et al.  Fibrinolytic Pathways and the Endothelium , 1987, Seminars in thrombosis and hemostasis.

[45]  Marcel Garcia,et al.  Estrogen‐induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? , 1987, Journal of cellular biochemistry.

[46]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[47]  L. Liotta,et al.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. , 1981, Cancer research.

[48]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .